UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
WILLIAM T. MORRISON, JR.,
Plaintiff,
v. Case No. 19-cv-1838 (CRC)
FEDERAL BUREAU OF PRISONS,
Defendant.
MEMORANDUM OPINION
Federal inmate William T. Morrison, Jr., proceeding pro se, filed suit alleging that the
Federal Bureau of Prisons (“BOP”) has mismanaged the treatment of his high cholesterol. He
requests a declaratory judgment stating that he is entitled to receive the nutritional supplement
Coenzyme Q10 (“CoQ10”) as part of his treatment. Although Morrison’s Amended Complaint
is somewhat unclear, the Court construes his claim as challenging his treatment under the Eighth
Amendment of the Constitution. The government has moved to dismiss on the merits and on
mootness grounds. Alternatively, it seeks a transfer of venue to the district where Morrison was
incarcerated when he filed suit. The Court rejects the government’s mootness and venue
arguments. But because Morrison has not alleged facts showing that BOP acted with deliberate
indifference to his medical needs, the Court will dismiss the case for failure to state an Eighth
Amendment violation.
I. Background
Mr. Morrison has been in BOP custody since February 2016. Am. Comp. at ¶9. When
he filed this suit in June 2019, he was housed at FCI Elkton in Ohio. Id. at 12. He now resides
at FCI El Reno in Oklahoma. See Notice of Change of Address, ECF. Dkt. No. 35. According to Morrison’s December 2019 Amended Complaint–––which the Court must accept as true at
this stage of the proceedings–––he has “a . . . family history of coronary heart disease,
[including] high levels of cholesterol,” and has been prescribed statin drugs to control his
cholesterol levels. See Am. Comp. at ¶¶10, 16. However, he complains that he is “highly
intolerant to statin medications,” and “suffers from common side effects” including muscle
cramps, joint pain, and fatigue. Id. at ¶17. To alleviate these side effects, Morrison states that
prison medical staff previously prescribed him CoQ10. Id. at ¶¶19–20. This combination of
statins and CoQ10 helped keep his cholesterol in the proper range and lessened the side effects
he had previously experienced while on statins alone. Id. at ¶23.
In 2017, Morrison was informed that CoQ10 could no longer be sold at inmate
commissaries. Id. at ¶25. Nevertheless, as Morrison was transferred around the federal prison
system, BOP approved his requests to maintain access to the supplement. See generally id. at
¶¶30–37. In late 2018, however, Morrison’s authorization for CoQ10 expired and the “FBOP
Central Office refused to approve” further requests for CoQ10 submitted by prison medical staff
on Morrison’s behalf. Id. at ¶¶38–40. According to medical records that Morrison attached to
his Amended Complaint, BOP denied his requests for CoQ10 because, as a nutritional
supplement, it is not FDA approved and it has not otherwise proven effective for the treatment of
the types of conditions that Morrison reported to prison medical staff. Am. Comp. Ex. F at 1. 1
1 While typically restricted to the pleadings when deciding a motion to dismiss for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6), a court may consider “documents attached as exhibits or incorporated by reference in the complaint.” Hinton v. Corr. Corp. of Am., 624 F. Supp. 2d 45, 46 (D.D.C. 2009) (internal quotation marks omitted); see also Marshall v. Honeywell Technology Solutions, Inc., 536 F. Supp. 2d 59, 65 (D.D.C. 2008) (“[W]here a document is referred to in the complaint and is central to the plaintiff's claim, such a document attached to the motion papers may be considered without converting the motion [to dismiss] to one for summary judgment.”) (internal quotation and citation omitted). Here,
2 Without the CoQ10, Morrison alleges that the side effects returned and he discontinued taking
his statin medication. Id. at ¶41. Morrison attempted to take various statins in 2019 without
CoQ10 but again experienced side effects and stopped taking them. See id. at ¶¶43–50.
After filing his initial complaint in this case and due to his reported intolerance to statins,
Morrison was prescribed Repatha, an injectable non-statin medication, with approval of BOP’s
Central Office. Id. at ¶50; Am. Comp. Ex. G at 1. Morrison acknowledges that the Repatha
injections lowered his cholesterol to normal levels. Am. Comp. at ¶50. Two months after
beginning the treatments, however, Morrison reported to FCI Elkton medical staff that he was
experiencing lower back pain, muscle aches, and plantar fasciitis, which he claims are side
effects of the Repatha. Id. (citing Am. Comp. Ex. H.) Prison medical staff treated his pain with
a steroid and provided him stretching exercises to relieve the reported plantar fasciitis. Am.
Comp. Ex. H. at 1. Morrison also claims in the Amended Complaint that he developed “fatigue”
and “unexplained nail fungus” as a result of taking Repatha, but there is no indication in the
attached medical records (nor does the Amended Complaint allege) that he brought these issues
to the attention of prison medical staff. Am. Comp. at ¶50.
Morrison seeks declaratory judgments that BOP “is obligated to provide adequate
medical care to [p]laintiff while he is in [its] care, custody, and control,” that his “[h]igh levels of
blood cholesterol [represent] a serious medical need,” and that he has a right to approval of his
non-formulary requests for CoQ10 as part of the treatment for his high cholesterol. Id. at 12.
The government has moved to dismiss Morrison’s suit for lack of subject matter jurisdiction due
Morrison has attached eight sets of prison medical records as exhibits to his Amended Complaint, which the Court will consider in deciding the present motion.
3 to mootness and for failure to state a claim. Alternatively, it seeks a transfer of venue to the
Southern District of Ohio, where Morrison was housed when he filed suit.
II. Analysis
Morrison’s complaint does not cite a specific cause of action supporting his claim of
mistreatment and is somewhat unclear as to the basis for his suit. See Am. Comp. at 1–12. The
Court will nonetheless construe his complaint liberally due to his pro se status. See, e.g.,
Sanchez-Mercedes v. Bureau of Prisons, 453 F. Supp. 3d 404, 415–16 (D.D.C. 2020). Because
the relief Morrison requests is equitable and makes express reference to his “serious medical
need[s]” (a phrase taken from Eighth Amendment caselaw), see Am. Comp. at 12, the Court
construes Morrison’s complaint as seeking a declaratory judgment vindicating his Eighth
Amendment right to be free from cruel and unusual punishment. So read, the Court has subject
matter jurisdiction under 28 U.S.C. § 1331 as Morrison’s claim “aris[es] under the Constitution.”
See Simmat v. U.S. Bureau of Prisons, 413 F.3d 1225, 1232 (10th Cir. 2005) (holding, in the
Free access — add to your briefcase to read the full text and ask questions with AI
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
WILLIAM T. MORRISON, JR.,
Plaintiff,
v. Case No. 19-cv-1838 (CRC)
FEDERAL BUREAU OF PRISONS,
Defendant.
MEMORANDUM OPINION
Federal inmate William T. Morrison, Jr., proceeding pro se, filed suit alleging that the
Federal Bureau of Prisons (“BOP”) has mismanaged the treatment of his high cholesterol. He
requests a declaratory judgment stating that he is entitled to receive the nutritional supplement
Coenzyme Q10 (“CoQ10”) as part of his treatment. Although Morrison’s Amended Complaint
is somewhat unclear, the Court construes his claim as challenging his treatment under the Eighth
Amendment of the Constitution. The government has moved to dismiss on the merits and on
mootness grounds. Alternatively, it seeks a transfer of venue to the district where Morrison was
incarcerated when he filed suit. The Court rejects the government’s mootness and venue
arguments. But because Morrison has not alleged facts showing that BOP acted with deliberate
indifference to his medical needs, the Court will dismiss the case for failure to state an Eighth
Amendment violation.
I. Background
Mr. Morrison has been in BOP custody since February 2016. Am. Comp. at ¶9. When
he filed this suit in June 2019, he was housed at FCI Elkton in Ohio. Id. at 12. He now resides
at FCI El Reno in Oklahoma. See Notice of Change of Address, ECF. Dkt. No. 35. According to Morrison’s December 2019 Amended Complaint–––which the Court must accept as true at
this stage of the proceedings–––he has “a . . . family history of coronary heart disease,
[including] high levels of cholesterol,” and has been prescribed statin drugs to control his
cholesterol levels. See Am. Comp. at ¶¶10, 16. However, he complains that he is “highly
intolerant to statin medications,” and “suffers from common side effects” including muscle
cramps, joint pain, and fatigue. Id. at ¶17. To alleviate these side effects, Morrison states that
prison medical staff previously prescribed him CoQ10. Id. at ¶¶19–20. This combination of
statins and CoQ10 helped keep his cholesterol in the proper range and lessened the side effects
he had previously experienced while on statins alone. Id. at ¶23.
In 2017, Morrison was informed that CoQ10 could no longer be sold at inmate
commissaries. Id. at ¶25. Nevertheless, as Morrison was transferred around the federal prison
system, BOP approved his requests to maintain access to the supplement. See generally id. at
¶¶30–37. In late 2018, however, Morrison’s authorization for CoQ10 expired and the “FBOP
Central Office refused to approve” further requests for CoQ10 submitted by prison medical staff
on Morrison’s behalf. Id. at ¶¶38–40. According to medical records that Morrison attached to
his Amended Complaint, BOP denied his requests for CoQ10 because, as a nutritional
supplement, it is not FDA approved and it has not otherwise proven effective for the treatment of
the types of conditions that Morrison reported to prison medical staff. Am. Comp. Ex. F at 1. 1
1 While typically restricted to the pleadings when deciding a motion to dismiss for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6), a court may consider “documents attached as exhibits or incorporated by reference in the complaint.” Hinton v. Corr. Corp. of Am., 624 F. Supp. 2d 45, 46 (D.D.C. 2009) (internal quotation marks omitted); see also Marshall v. Honeywell Technology Solutions, Inc., 536 F. Supp. 2d 59, 65 (D.D.C. 2008) (“[W]here a document is referred to in the complaint and is central to the plaintiff's claim, such a document attached to the motion papers may be considered without converting the motion [to dismiss] to one for summary judgment.”) (internal quotation and citation omitted). Here,
2 Without the CoQ10, Morrison alleges that the side effects returned and he discontinued taking
his statin medication. Id. at ¶41. Morrison attempted to take various statins in 2019 without
CoQ10 but again experienced side effects and stopped taking them. See id. at ¶¶43–50.
After filing his initial complaint in this case and due to his reported intolerance to statins,
Morrison was prescribed Repatha, an injectable non-statin medication, with approval of BOP’s
Central Office. Id. at ¶50; Am. Comp. Ex. G at 1. Morrison acknowledges that the Repatha
injections lowered his cholesterol to normal levels. Am. Comp. at ¶50. Two months after
beginning the treatments, however, Morrison reported to FCI Elkton medical staff that he was
experiencing lower back pain, muscle aches, and plantar fasciitis, which he claims are side
effects of the Repatha. Id. (citing Am. Comp. Ex. H.) Prison medical staff treated his pain with
a steroid and provided him stretching exercises to relieve the reported plantar fasciitis. Am.
Comp. Ex. H. at 1. Morrison also claims in the Amended Complaint that he developed “fatigue”
and “unexplained nail fungus” as a result of taking Repatha, but there is no indication in the
attached medical records (nor does the Amended Complaint allege) that he brought these issues
to the attention of prison medical staff. Am. Comp. at ¶50.
Morrison seeks declaratory judgments that BOP “is obligated to provide adequate
medical care to [p]laintiff while he is in [its] care, custody, and control,” that his “[h]igh levels of
blood cholesterol [represent] a serious medical need,” and that he has a right to approval of his
non-formulary requests for CoQ10 as part of the treatment for his high cholesterol. Id. at 12.
The government has moved to dismiss Morrison’s suit for lack of subject matter jurisdiction due
Morrison has attached eight sets of prison medical records as exhibits to his Amended Complaint, which the Court will consider in deciding the present motion.
3 to mootness and for failure to state a claim. Alternatively, it seeks a transfer of venue to the
Southern District of Ohio, where Morrison was housed when he filed suit.
II. Analysis
Morrison’s complaint does not cite a specific cause of action supporting his claim of
mistreatment and is somewhat unclear as to the basis for his suit. See Am. Comp. at 1–12. The
Court will nonetheless construe his complaint liberally due to his pro se status. See, e.g.,
Sanchez-Mercedes v. Bureau of Prisons, 453 F. Supp. 3d 404, 415–16 (D.D.C. 2020). Because
the relief Morrison requests is equitable and makes express reference to his “serious medical
need[s]” (a phrase taken from Eighth Amendment caselaw), see Am. Comp. at 12, the Court
construes Morrison’s complaint as seeking a declaratory judgment vindicating his Eighth
Amendment right to be free from cruel and unusual punishment. So read, the Court has subject
matter jurisdiction under 28 U.S.C. § 1331 as Morrison’s claim “aris[es] under the Constitution.”
See Simmat v. U.S. Bureau of Prisons, 413 F.3d 1225, 1232 (10th Cir. 2005) (holding, in the
context of an Eighth Amendment claim for equitable relief due to denial of medical treatment,
that “Section 1331 [] provides jurisdiction for the exercise of the traditional powers of equity in
actions arising under” the Eighth Amendment). 2
A. Mootness
The government moves to dismiss the action on the grounds that the suit is moot because
Morrison is now receiving medication which keeps his cholesterol within normal levels. See
Mot. to Dismiss at 5–6. However, while Morrison’s initial complaint focused on the treatment of
2 Morrison also correctly notes that the waiver of sovereign immunity in the Administrative Procedure Act, 5 U.S.C. § 702, would apply to such a suit. Simmat, 413 F.3d at 1233; see also Chamber of Commerce v. Reich, 74 F.3d 1322, 1329 (D.C. Cir. 1996) (“The APA's waiver of sovereign immunity applies to any suit whether under the APA or not.”).
4 his high cholesterol, the Amended Complaint does not solely––or even primarily––concern his
cholesterol levels. It rather focuses on the side effects he allegedly experiences as a result of his
Repatha injections, side effects Morrison says would be absent were he provided access to
CoQ10 in combination with statins. See Am. Comp. at ¶¶50–53. The government’s arguments
regarding Morrison’s cholesterol levels are thus misplaced; the relevant harms are the purported
Repatha side effects. As discussed below, these side effects may or may not be sufficiently
serious to ground an Eighth Amendment claim, see infra II.C, but they are enough to save
Morrison’s suit from mootness.
B. Venue
The government also moves to transfer venue to the Southern District of Ohio, arguing
that is where “Plaintiff can be found as well as where his medical records and witness may also
be found.” Mot. to Dismiss at 8. However, Morrison’s central allegation is that the denial of his
CoQ10 medication was a decision made by the “FBOP Central Office” located in Washington,
D.C. See, e.g., id. at ¶29. Further, given that Morrison received treatment at various BOP
facilities during the time period covered by the Amended Complaint, see, e.g., id. at ¶42, and has
subsequently been relocated from Ohio to Oklahoma, see Notice of Change of Address, ECF.
Dkt. No. 35, there is little to be gained in terms of convenience of the parties and witnesses by
transferring this matter to Ohio. The Court therefore denies the government’s request to transfer
venue.
C. Eighth Amendment Claim
To establish a claim under the Eighth Amendment for denial of adequate medical care
while incarcerated, a plaintiff must show that he suffered from a serious medical need and that
5 prison officials were deliberately indifferent to that need. See Banks v. York, 515 F. Supp. 2d
89, 102 (D.D.C. 2007); see also Estelle v. Gamble, 429 U.S. 97, 103–04 (1976).
As to the first requirement, the D.C. Circuit has given little guidance on what a plaintiff
must show to establish that he suffered from a serious medical need. See Woodruff v. United
States, No. CV 16-1884 (RDM), 2020 WL 3297233, at *10 (D.D.C. June 18, 2020) (noting “the
absence of controlling D.C. Circuit case law [] regarding what it means for a prisoner to have a
‘serious medical need’”). Fellow district courts to have confronted the question have found a
serious medical need where the prisoner is suffering from an ailment which the general public
would easily recognize as demanding medical intervention, or, in some cases, where the ailment
has been previously diagnosed and treated by a physician. See, e.g., Chandler v. Stover, 211 F.
Supp. 3d 289, 301 (D.D.C. 2016) (“[a] medical need is serious if it is one that has been
diagnosed by a physician as mandating treatment or one that is so obvious that even a lay person
would easily recognize the necessity for a doctor's attention”).
Morrison complains of muscle cramps, fatigue, and an unexplained nail fungus due to his
Repatha injections. Am. Comp. at ¶50. The Court questions whether these conditions are
sufficiently serious to ground an Eighth Amendment claim. See Roberson v. Manasrah, No.
117CV01062DADSAB, 2019 WL 1517721, at *1 (E.D. Cal. Apr. 8, 2019) (dismissing Eighth
Amendment claim for failure to show serious medical need where plaintiff “submitted forms
complaining of shortness of breath, muscle cramping, chest pain, joint pain, severe headaches,
night sweats, and coughing”); but see Merritte v. Arbuckle, No. 16-CV-0959-NJR, 2016 WL
7174663, at *3 (S.D. Ill. Dec. 8, 2016) (Eighth Amendment claim permitted to proceed after
plaintiff “experienced muscle cramps, hunger pains, migraines, and lethargy as a result of
receiving meal trays with beans” to which he was allergic). The Court need not decide this issue,
6 however, because it concludes that Morrison has failed to allege facts showing that BOP medical
personnel acted with deliberate indifference to the purported side effects of the Repatha
injections.
Deliberate indifference in violation of the Eighth Amendment must “constitute[]
unnecessary and wanton infliction of pain contrary to contemporary standards of decency.”
Helling v. McKinney, 509 U.S. 25, 32 (1993) (citing Estelle, 429 U.S. at 104). It is “a state of
mind more blameworthy than negligence,” Farmer v. Brennan, 511 U.S. 825, 835 (1994), and
more akin to “criminal recklessness,” Barr v. Pearson, 909 F.3d 919, 922 (8th Cir. 2018). As
relevant here, “mere disagreement over the proper treatment” cannot support a finding of
deliberate indifference. Banks, 515 F. Supp 2d at 103 (quoting Chance v. Armstrong, 143 F.3d
698, 703 (2d. Cir. 1998)).
Morrison has not met this demanding standard. As noted above, the documents attached
to Morrison’s complaint attest that the prison medical personnel responsible for his care
prescribed treatment for the main side effects from Repatha that Morrison reported to them. See
Am. Comp. Ex. H at 1 (prescribing an anti-inflammatory steroid for reported lower-back pain
and muscle aches and providing Morrison with stretching exercises to relieve his plantar
fasciitis). Where prison medical officials provide treatment for the medical issue in question,
“‘[a] prisoner's mere difference of opinion over matters of expert medical judgment or a course
of medical treatment’” does not amount to a showing of deliberate indifference on the part of the
prison’s medical staff. Barr, 909 F.3d at 921–22 (quoting Meuir v. Greene Cty. Jail Emps., 487
F.3d 1115, 1118–19 (8th Cir. 2007)); see also id. at 922 (finding no deliberate indifference where
prison officials “continued to provide medical care” including “providing other medication” to
7 treat an inmate after side effects caused medical officials to end a course of treatment the
plaintiff favored). 3
Although the focus of Morrison’s claim is, as noted above, the side effects he currently
experiences from Repatha, he similarly fails to allege facts showing that the BOP’s refusal to
provide him with CoQ10 was the result of deliberate indifference. The medical records attached
to Morrison’s complaint indicate that BOP officials refused this request because (1) there was
“little published evidence showing benefit of [CoQ10] for the treatment of myopathy” 4 and (2)
BOP generally does not approve the use of nutritional supplements, which are not FDA
approved. Am. Comp. Ex. F at 1. Moreover, Morrison acknowledges that BOP’s administration
of Repatha as an alternative to statins and CoQ10 (and which was approved by the Central
Office) was effective in lowering his cholesterol to normal levels. Am. Comp. at ¶50.
Morrison’s disagreements with the medical judgments underlying both the refusal to provide him
CoQ10 and the treatment provided for his Repatha-related side effects are thus insufficient to
show that BOP officials were deliberately indifferent to his medical needs. See Bryant v.
Wright, 451 F. App’x. 12 (2d Cir. 2011) (finding no deliberate indifference where prescription of
3 Although Morrison’s Amended Complaint alleges that he also suffers from an unexplained nail fungus, he does not allege––nor do the medical records attached to his complaint show––that prison medical staff were aware of this ailment. See Am. Comp. Ex. H at 1. Absent such awareness, any failure to treat the fungus cannot show deliberate indifference. See Baker v. District of Columbia, 326 F.3d 1302, 1306 (D.C. Cir. 2003) (“To show deliberate indifference, [a plaintiff must] allege that [the defendant] had subjective knowledge of [a] serious medical need and recklessly disregarded the excessive risk to inmate health or safety from that risk.” (emphasis added)). As for Morrison’s unspecific complaints of “fatigue,” a prison doctor's refusal to “dispense bromides for the sniffles or minor aches and pains or a tiny scratch or a mild headache or minor fatigue . . . does not violate the Constitution.” Cooper v. Casey, 97 F.3d 914, 916 (7th Cir.1996). 4 “Myopathy” is a general term that encompasses the muscle pain and cramping that Morrison reported to FCI Elkton medical staff per the attached records.
8 generic medications caused inmate to suffer side effects because choice of medication was a
common exercise of judgment and doctors worked to treat the side effects).
Finally, in the rare cases where courts have entertained Eighth Amendment claims arising
from the alleged insufficiency of a physician’s choice of treatment, they have required plaintiffs
to allege facts showing a more culpable mental state than that associated with merely “‘fail[ing]
to provide the [allegedly] more efficacious treatment.’” See Banks, 515 F. Supp. 2d at 103
(quoting O’Connor v. McArdle, 217 F. App’x. 81, 83 (2d Cir. 2007)); see also id. (noting that
cases where plaintiffs successfully maintain a claim for deliberate indifference based on the
purported shortcomings of the treatment received require the plaintiffs to allege, e.g., financial
motives or other suspect incentives behind the physician’s choice of treatment). Morrison’s
complaint does not in any way suggest that BOP’s treatment of his high cholesterol or the
Repatha side effects emerged from any such improper motive or culpable mental state. See Am.
Comp. at 1–12. He thus cannot maintain a suit for an Eighth Amendment violation based on his
dissatisfaction with the course of treatment chosen or approved by BOP personnel.
III. Conclusion
For the foregoing reasons, the Court will grant [28] Defendant’s Motion to Dismiss for
failure to state a claim on which relief can be granted. A separate order will follow.
CHRISTOPHER R. COOPER United States District Judge
Date: March 30, 2021